Vir Biotechnology Inc Total Liabilities
Vir Biotechnology Inc total liabilities. Based on the latest financial reports, Vir Biotechnology Inc (VIR) has total liabilities worth $232.31 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VIR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vir Biotechnology Inc (2017–2025)
Total liabilities of Vir Biotechnology Inc from 2017 to 2025. This chart illustrates how Vir Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore VIR long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Vir Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Vir Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
USA | $37.44 Billion |
|
China Enterprise Co Ltd
SHG:600675
|
China | CN¥34.01 Billion |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
China | CN¥7.15 Billion |
|
Xinhua Winshare Publishing and Media Co Ltd
SHG:601811
|
China | CN¥7.71 Billion |
|
EMBOTELL. ANDINA ADR A/6
F:AKOA
|
Germany | €2.13 Trillion |
|
Ziff Davis Inc
NASDAQ:ZD
|
USA | $1.76 Billion |
|
Primarius Technologies Co. Ltd. A
SHG:688206
|
China | CN¥436.31 Million |
|
Region Group
AU:RGN
|
Australia | AU$1.81 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Vir Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Vir Biotechnology Inc assets under control.
Liquidity & Leverage Metrics
Vir Biotechnology Inc Total Liabilities Ratios Explained
Vir Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vir Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vir Biotechnology Inc (2017–2025)
The table below shows the annual total liabilities of Vir Biotechnology Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $237.55 Million | -4.38% |
| 2024-12-31 | $248.43 Million | -24.45% |
| 2023-12-31 | $328.82 Million | -54.59% |
| 2022-12-31 | $724.12 Million | +38.61% |
| 2021-12-31 | $522.42 Million | +158.74% |
| 2020-12-31 | $201.91 Million | +129.11% |
| 2019-12-31 | $88.13 Million | -76.23% |
| 2018-12-31 | $370.77 Million | +15.69% |
| 2017-12-31 | $320.48 Million | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more